

# MARKET REPORT



Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk)

# Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018

## Summary

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and post-translational levels.

It mediates survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 7 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Immunology which include indications Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Bladder Cancer, Diffuse Large B-Cell Lymphoma, Hematological Tumor, Lymphoma, Myocardial Infarction, Non-Small Cell Lung Carcinoma, Pancreatic Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)

- The report reviews Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

<https://www.bioportfolio.co.uk/product/227545>  
[pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) to order

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Additional Details

**Publisher** : Global Markets Direct

**Reference** : GMDHC1783TDB

**Number of Pages** : 47

**Report Format** : PDF

**Publisher Information** :

**Global Markets Direct**  
The home of leading edge research and analysis

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018]

- Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageSerine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - OverviewSerine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Therapeutics DevelopmentProducts under Development by Stage of DevelopmentProducts under Development by Therapy AreaProducts under Development by IndicationProducts under Development by CompaniesProducts under Development by Universities/InstitutesSerine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Therapeutics AssessmentAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeSerine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Companies Involved in Therapeutics DevelopmentIncyte CorpInfection Biosciences LtdJasco Pharmaceuticals LLCNovartis AGSanofiSARomics Biostructures ABTolero Pharmaceuticals IncYakult Honsha Co LtdSerine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Drug ProfilesGene Therapy to Activate PIM1 for Myocardial Infarction - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressIBL-100 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressINCB-53914 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressLGB-321 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSBX-1501 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule to Inhibit CSNK2 and PIM1 for Oncology - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule to Inhibit PIM1 and PIM3 for Oncology - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules to Inhibit Pim Kinase for Pancreatic Cancer - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules to Inhibit Pim-1 for Prostate Cancer - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules to Inhibit PIM1 and PIM2 for Oncology - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSMI-4a - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTP-3654 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSerine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Dormant ProductsSerine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Discontinued ProductsSerine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Product Development MilestonesFeatured News & Press ReleasesOct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast CancerOct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic OncologyJun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial CarcinomaApr 01, 2013: Jasco Pharma To Present Data On PIM Inhibitor Program At AACR Annual Meeting 2013Mar 31, 2011: Jasco Pharma To Present Data On Preclinical PIM Inhibitor Program At AACR Annual MeetingAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer

# How to Buy...

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/227545>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$3080** | Single User Price
- \$6160** | Site License Price
- \$9240** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.